Sabine Brookman-May: SWOGS1011 finally published in NEJM

Sabine Brookman-May shared a post on X by NEJM about a recent paper by Seth Lerner et al. published in NEJM.

“Standard or Extended Lymphadenectomy for Muscle-Invasive Bladder Cancer”

Authors: Seth Lerner, Catherine Tangen, Robert Svatek, Daniel Canter, Ian Thompson et al.

“SWOGS1011 finally published in NEJM.

• Extended LND in MIBC did not improve OS/DFS vs. standard LND
• Higher morbidity/mortality with extended LND

Thank you, Seth Lerner, SWOG Cancer Research Network for answering this question finally!”

Quoting The New England Journal of Medicine (NEJM)’s post:

“In patients with muscle-invasive bladder cancer, extended lymphadenectomy did not improve disease-free or overall survival as compared with the standard procedure and was associated with higher morbidity and mortality. Full SWOG S1011 trial results.”

Sources: Sabine Brookman-May/X and NEJM/X

More posts featuring Sabine Brookman-May.

Sabine D. Brookman-May is the Senior Vice President and Therapeutic Area Head of Urologic Oncology at Aura Biosciences. Previously, she was the Vice President of Bladder Cancer Development, Research and Development at Janssen Pharmaceutical Companies of Johnson & Johnson. She also serves as a professor of Urology at Ludwig Maximilian University of Munich, specializing in Urology, Oncology, and Sports and Exercise Medicine.